anti-CD19 UCAR-NK
/ Chongqing Precision Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 06, 2022
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Kunming Hope of Health Hospital
New P1/2 trial • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation
1 to 1
Of
1
Go to page
1